176 related articles for article (PubMed ID: 35213039)
1. Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy.
Poterala JE; Wisinski KB
Cancer; 2022 May; 128(9):1724-1726. PubMed ID: 35213039
[No Abstract] [Full Text] [Related]
2. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
Mayer EL; Burstein HJ
Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
[TBL] [Abstract][Full Text] [Related]
3. Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics.
Chandler Y; Schechter C; Jayasekera J; Isaacs C; Kurian AW; Cadham C; Mandelblatt J
Cancer Med; 2022 Jan; 11(2):297-307. PubMed ID: 34918484
[TBL] [Abstract][Full Text] [Related]
4. Optimizing endocrine therapy in premenopausal ER-positive breast cancer patients.
Ruddy KJ; Partridge AJ
Oncology (Williston Park); 2009 Jan; 23(1):34, 40. PubMed ID: 19283919
[No Abstract] [Full Text] [Related]
5. Optimal adjuvant endocrine therapy for early breast cancer.
Stuart-Harris R; Davis A
Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
7. In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Lykkesfeldt AE; Henriksen KL; Rasmussen BB; Sasano H; Evans DB; Møller S; Ejlertsen B; Mouridsen HT
BMC Cancer; 2009 Jun; 9():185. PubMed ID: 19531212
[TBL] [Abstract][Full Text] [Related]
8. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
Petrelli F; Barni S
Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
[No Abstract] [Full Text] [Related]
9. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant endocrine therapy in breast cancer.
Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
[TBL] [Abstract][Full Text] [Related]
11. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine therapy for premenopausal hormone receptor-positive breast cancer; much done, more to do.
Higgins MJ; Wolf AC
Oncology (Williston Park); 2009 Jan; 23(1):40, 42, 44. PubMed ID: 19283920
[No Abstract] [Full Text] [Related]
13. [Advancement in endocrine therapy for breast cancer].
Yang MT; Lian ZQ
Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
[TBL] [Abstract][Full Text] [Related]
14. [New options in adjuvant endocrine therapy in breast cancer].
Saltel-Fulero A; Donnadieu A; Leman-Detours S; Cottu P
Bull Cancer; 2016 Jan; 103(1):104-12. PubMed ID: 26675809
[TBL] [Abstract][Full Text] [Related]
15. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
Dowsett M; Johnston S; Martin LA; Salter J; Hills M; Detre S; Gutierrez MC; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Smith I
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S113-7. PubMed ID: 16113087
[TBL] [Abstract][Full Text] [Related]
16. [Adjuvant treatment of breast cancer. Endocrine therapy].
Mouridsen HT; Andersen J
Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
[TBL] [Abstract][Full Text] [Related]
17. Extended Endocrine Therapy: Is 5 Years Enough?
Bhave MA; Henry NL
Curr Oncol Rep; 2017 Mar; 19(3):16. PubMed ID: 28251491
[TBL] [Abstract][Full Text] [Related]
18. Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer.
Gemignani ML; Hetzel DJ
Gynecol Oncol; 2017 Oct; 147(1):153-157. PubMed ID: 28662774
[No Abstract] [Full Text] [Related]
19. Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Bedard PL; Piccart-Gebhart MJ
Curr Opin Oncol; 2009 Nov; 21(6):491-8. PubMed ID: 19593135
[TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
